Sven Meuth

Prof. S. Meuth
Arzt-Klinikdirektor-Wissenschaftler
Aktuelle Informationen aus der Neurologie
Reine Nervensache Blog: coming soon

[Sven Meuth @rn_meuth]

Der Weg zu unserer MS Ambulanz https://t.co/FbcWtqn6pa via @YouTube

[Sven Meuth @rn_meuth]

Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany https://t.co/pLgDnEBxY5

[Sven Meuth @rn_meuth]

Check out our recent publication on how digital tools are increasingly being validated and used in neurological clinical trials!
Great interdisciplinary project with @LarsMasanneck @arieldora Pauline Gieseler and William Gordon!

[Ariel Dora Stern @arieldora]

New in @npjDigitalMed with @LarsMasanneck Pauline Giesleler @willjg & @rn_meuth: the growth of digital health technologies in neurology research 🤳📈📲🙌

+ data on how tech has changed over the last decade: motor/sleep/cognition tracking, adherence, caregiver support & more! 👇

[npj Digital Medicine @npjDigitalMed]

The share of neurological clinical trials using #digitalhealth technologies has increased from <1% in 2010 to >10% in 2021.

What will it look like in another 11 years?

https://t.co/zEupLBBlKm

[Sven Meuth @rn_meuth]

Neuron-oligodendrocyte potassium shuttling at nodes of Ranvier protects against inflammatory demyelination https://t.co/MrhwoPECBl

[Sven Meuth @rn_meuth]

Cerebrospinal fluid proteomics indicates immune dysregulation and neuronal dysfunction in antibody associated autoimmune encephalitis https://t.co/ksKs4qwySy

[Sven Meuth @rn_meuth]

Neuro?Logisch! 2.0 https://t.co/v2BMlKgv39

[Sven Meuth @rn_meuth]

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses https://t.co/x7qk0uaRE6

[Sven Meuth @rn_meuth]

Neue DFG-Forschungsgruppe zu Untersuchungen zur Ambivalenz des AHR-Signalweges in Hautkrankheiten mit Beteiligung der Neurologie des UKD https://t.co/chsrs90II9

[Sven Meuth @rn_meuth]

05.10.2022- Tag der Epilepsie https://t.co/2GE5mnsSkG

[Sven Meuth @rn_meuth]

Tirzepatid zur Behandlung von Adipositas https://t.co/AqStI31PZl

[Sven Meuth @rn_meuth]

Ublituximab zur Behandlung der Multiplen Sklerose https://t.co/QmoOt85Xdp

[Sven Meuth @rn_meuth]

Was verbirgt sich hinter dem Uhthoff-Phänomen? https://t.co/no2iIyXwmv

[Sven Meuth @rn_meuth]

Expertenkonsens zum Langzeitmanagement von MS-Patient:innen unter Cladribin-Tabletten https://t.co/1RnEMcQ6TU

[Sven Meuth @rn_meuth]

Die Europäische Kommission hat Efgartigimod die Zulassung für die Behandlung, zusätzlich zur Standardtherapie, von erwachsenen PatientInnen mit generalisierter Myasthenia gravis, die Anti-Acetylcholin-Rezeptor-Antikörper positiv sind, erteilt.

[Sven Meuth @rn_meuth]

Machine Learning für Schädel-CTs – neue Wege für mehr Daten und bessere Modelle  https://t.co/eMErOmKEhG

[Sven Meuth @rn_meuth]

Eine lesenswerte Arbeit! https://t.co/zO43ISkzim

[Sven Meuth @rn_meuth]

Thinking outside the box: non-canonical targets in multiple sclerosis. https://t.co/U7dL3uIiLb

[Sven Meuth @rn_meuth]

Update zu Efgartigmod für Myasthenia gravis https://t.co/7QdtGJQPK4

[Sven Meuth @rn_meuth]

Welt-ALS Tag 2022 – ein Kommentar https://t.co/Ehq1wZAJOc